Heparin addition to chemotherapy improves survival in advanced pancreatic cancer
This article has no abstract so we have provided the first paragraph of the full text.
Combined gemcitabine (GEM) and cisplatin (CDDP) chemotherapy is a promising strategy for the treatment of patients with advanced pancreatic cancer. Low molecular weight heparin (LMWH) has been shown to have antitumoral activity; however, there are no data regarding the activity of LMWH in pancreatic cancer. In a recent nonrandomized trial, Icli et al. assessed the effect of adding LMWH to GEM–CDDP chemotherapy in the treatment of patients with advanced pancreatic cancer.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.